---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-046671"
form_type: "8-K"
ticker: "APUS"
cik: "0001894525"
company_name: "Apimeds Pharmaceuticals US, Inc."
filed_at: "2026-04-22T23:59:59+00:00"
generated_at: "2026-05-15T04:56:22.289061+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Apimeds gets NYSE American delisting notice for late 10-K; trading halt continues

## Summary
- Received NYSE American notice on April 17, 2026 for failure to file 2025 10-K on time.
- Has initial 6-month cure period until October 15, 2026; expects to file 10-K by April 30.
- Common stock trades with '.LF' designation; trading halt from April 2 remains in effect.
- If not cured, NYSE may grant up to 6 additional months or commence delisting procedures.

## SEC filing metadata
- accession: 0001213900-26-046671
- form_type: 8-K
- ticker: APUS
- cik: 0001894525
- company_name: Apimeds Pharmaceuticals US, Inc.
- filed_at: 2026-04-22T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1894525/000121390026046671/0001213900-26-046671-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1894525/000121390026046671/ea028720301-8k_apimeds.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-046671
- JSON: https://secwatch.observer/filing/0001213900-26-046671.json
- Plain text: https://secwatch.observer/filing/0001213900-26-046671.txt

## Key facts
- Listing & Compliance Notices
  Apimeds Pharmaceuticals US, Inc. received a nyse_american deficiency notice notice regarding late filing (rules 1007).
  - Exchange: nyse american
  - Notice: deficiency notice
  - Deficiency: late filing
  - Rules: 1007
  source text: April 17, 2026, Apimeds Pharmaceuticals US, Inc. (the “ Company ”) received a notice from the NYSE Regulation staff of the New York Stock Exchange (“ NYSE ”) indicating that the Company is not in compliance with NYSE’s continued listing requirements under the timely filing criteria outlined in Section 1007 of the NYSE American Listed Company Manual as a result of the Company’s failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the “ Form 10-K ”). NYSE informed the Company that the Company will have an initial cure period of six months from April
  evidence_url: https://www.sec.gov/Archives/edgar/data/1894525/000121390026046671/0001213900-26-046671-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.